%0 Journal Article
%A Santoro, Francesco
%A Nuñez-Gil, Ivan Javier
%A Vitale, Enrica
%A Viana-Llamas, Maria C
%A Reche-Martinez, Begoña
%A Romero-Pareja, Rodolfo
%A Feltez Guzman, Gisela
%A Fernandez Rozas, Inmaculada
%A Uribarri, Aitor
%A Becerra-Muñoz, Víctor Manuel
%A Alfonso-Rodriguez, Emilio
%A Garcia-Aguado, Marcos
%A Huang, Jia
%A Ortega-Armas, María Elizabeth
%A Garcia Prieto, Juan F
%A Corral Rubio, Eva Maria
%A Ugo, Fabrizio
%A Bianco, Matteo
%A Mulet, Alba
%A Raposeiras-Roubin, Sergio
%A Jativa Mendez, Jorge Luis
%A Espejo Paeres, Carolina
%A Albarrán, Adrián Rodríguez
%A Marín, Francisco
%A Guerra, Federico
%A Akin, Ibrahim
%A Cortese, Bernardo
%A Ramakrishna, Harish
%A Macaya, Carlos
%A Fernandez-Ortiz, Antonio
%A Brunetti, Natale Daniele
%T Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry.
%D 2021
%U http://hdl.handle.net/10668/20155
%X Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival. 7824 consecutive patients with COVID-19 were enrolled in a multicentre international prospective registry (Health Outcome Predictive Evaluation-COVID-19 Registry). Clinical data and in-hospital complications were recorded. Data on APT, including aspirin and other antiplatelet drugs, were obtained for each patient. During hospitalisation, 730 (9%) patients received single APT (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (74±12 years vs 63±17 years, p APT during hospitalisation for COVID-19 could be associated with lower mortality risk and shorter duration of mechanical ventilation, without increased risk of bleeding. NCT04334291.
%K COVID-19
%K clinical
%K pharmacology
%~